| Autor: |
David Lubkowicz, Nicholas G Horvath, Michael J James, Pasquale Cantarella, Lauren Renaud, Christopher G Bergeron, Ron B Shmueli, Cami Anderson, Jian‐Rong Gao, Caroline B Kurtz, Mylene Perreault, Mark R Charbonneau, Vincent M Isabella, David L Hava |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Molecular Systems Biology, Vol 18, Iss 3, Pp 1-17 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1744-4292 |
| DOI: |
10.15252/msb.202110539 |
| Popis: |
Abstract Enteric hyperoxaluria (EH) is a metabolic disease caused by excessive absorption of dietary oxalate leading to the formation of chronic kidney stones and kidney failure. There are no approved pharmaceutical treatments for EH. SYNB8802 is an engineered bacterial therapeutic designed to consume oxalate in the gut and lower urinary oxalate as a potential treatment for EH. Oral administration of SYNB8802 leads to significantly decreased urinary oxalate excretion in healthy mice and non‐human primates, demonstrating the strain's ability to consume oxalate in vivo. A mathematical modeling framework was constructed that combines in vitro and in vivo preclinical data to predict the effects of SYNB8802 administration on urinary oxalate excretion in humans. Simulations of SYNB8802 administration predict a clinically meaningful lowering of urinary oxalate excretion in healthy volunteers and EH patients. Together, these findings suggest that SYNB8802 is a promising treatment for EH. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
